Indeed, numerous clinical trials have investigated the application of mTOR inhibitors, including temsirolimus, sirolimus, and rapamycin, either as standalone treatments or in conjunction with other therapies, for conditions such as atherosclerosis, autoimmune disorders, and malignant tumors. The gene discussed is MTOR; the disease is atherosclerosis.